Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?

Hologic (HOLX) is experiencing a slowdown in its Breast Health segment, with sales declining 6.2% in fiscal Q2 2025 due to weaker capital equipment sales, leading to a forecast of a low-single-digit decline for the year. Despite this, service revenues grew 12%, supported by a large installed base, and the company anticipates a growth rebound in Q4, driven by their dominant 3D Genius mammography machine and the upcoming launch of the Envision platform in fiscal 2026; however, HOLX shares have dropped 12.6% YTD, underperforming the industry, and its earnings estimates for fiscal years 2025 and 2026 have been revised downward.

Analysis

Hologic is currently navigating a challenging period within its core Breast Health segment, which experienced a 6.2% sales decline in the fiscal 2025 second quarter, extending a 2.1% drop from the prior quarter, primarily due to weaker capital equipment sales following two years of elevated post-chip shortage mammography shipments. Consequently, the company forecasts a low-single-digit decline for Breast Health for the full year, with a mid-single-digit organic decline. Despite this capital equipment softness, Hologic's recurring service revenues, stemming from its substantial global installed base of nearly 15,000 gantries and forming the segment's largest contributor, grew a robust 12% year-over-year in the second quarter, highlighting the stability of this revenue stream where Hologic holds nearly 80% of the U.S. market with its 3D Genius mammography machine. Management anticipates a return to growth in the fourth quarter and is banking on future catalysts, including the commercial launch of its FDA-cleared Envision mammography platform in fiscal 2026 and the integration of the 2024 Endomagnetics acquisition to bolster its Interventional Breast portfolio. In contrast, competitor GE Healthcare reported record double-digit order growth and a 5% organic increase in imaging revenues in its recent quarter, while Becton Dickinson, despite a Q2 dip in its broader Interventional segment, expects stronger second-half growth. Hologic's stock has underperformed, declining 12.6% year-to-date, exceeding the industry's 9.8% fall, and trades at a forward 12-month earnings multiple of 14.02X, significantly below the industry average of 28.64X. However, Zacks Consensus Estimates for Hologic's earnings for fiscal 2025 and 2026 have been revised downward over the past 90 days, and the stock currently carries a Zacks Rank #4 (Sell).

Key Decisions for Investors

• Investors should closely monitor Hologic's capital equipment sales for tangible signs of the anticipated Q4 rebound, as management's optimism currently contrasts with observed downward trends and negative earnings revisions.
• The sustained growth in Hologic's service revenues, driven by its large installed base, and the successful market adoption of the Envision platform post-its fiscal 2026 launch, will be critical indicators of the company's ability to offset capital sales volatility and achieve its long-term growth objectives.
• Given Hologic's current stock underperformance, downward earnings estimate revisions, and a Zacks Rank #4 (Sell), a cautious approach is warranted; while the valuation appears attractive relative to peers (14.02X P/E vs. 28.64X industry), await concrete evidence of operational improvements and positive estimate momentum before considering new or increased positions.